Keywords
Last Name

Adam Lerner, MD

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHematology & Medical Oncology
Address650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Phone(617) 638-7504
ORCID ORCID Icon0000-0001-9259-7868
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentPathology & Laboratory Medicine

TitleActive Staff Privileges
InstitutionBoston Medical Center
DepartmentMedicine
DivisionHematology & Medical Oncology

 Research Expertise & Professional Interests
Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.

 Self-Described Keywords
  • Breast cancer
  • cAMP
  • CLL
  • Phosphodiesterases
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428.
    View in: PubMed
  2. Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016 Sep; 38:223-32. PMID: 27302770.
    View in: PubMed
  3. Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015; 6:230. PMID: 26528184.
    View in: PubMed
  4. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015; 56(10):2847-54. PMID: 25791237.
    View in: PubMed
  5. Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015 Jan 1; 194(1):101-12. PMID: 25416804.
    View in: PubMed
  6. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar; 168(6):811-9. PMID: 25404094.
    View in: PubMed
  7. Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014; 2:16. PMID: 25279222.
    View in: PubMed
  8. Tapan U, Pestana JB, Lee JC, Lerner A. Epstein-Barr virus-associated diffuse large B-cell lymphoma arising in atrial myxoma: a proposal for a modified therapeutic approach. Leuk Lymphoma. 2015 Feb; 56(2):505-7. PMID: 24794809.
    View in: PubMed
  9. Jennings L, Campbell SM, Yaar R, Mahalingam M, Sahni D, Lerner A, Rünger TM. Generalized syringotropic mycosis fungoides responsive to extracorporeal photopheresis. Br J Dermatol. 2014 Jan; 170(1):200-2. PMID: 23909445.
    View in: PubMed
  10. Kim YH, Demierre MF, Kim EJ, Lerner A, Rook AH, Duvic M, Robak T, Samtsov A, McCulloch W, Chen SC, Waksman J, Nichols J, Whittaker S. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma. 2013 Feb; 54(2):284-9. PMID: 22839723.
    View in: PubMed
  11. Makkinje A, Vanden Borre P, Near RI, Patel PS, Lerner A. Breast cancer anti-estrogen resistance 3 (BCAR3) protein augments binding of the c-Src SH3 domain to Crk-associated substrate (p130cas). J Biol Chem. 2012 Aug 10; 287(33):27703-14. PMID: 22711540.
    View in: PubMed
  12. Schieke SM, Sharaf MA, Lerner A, Rünger TM, Mahalingam M. Primary cutaneous CD56 positive lymphoma: a diagnostic conundrum in an unusual case of lymphoma. J Cutan Pathol. 2012 May; 39(5):540-4. PMID: 22519525.
    View in: PubMed
  13. Lerner A, Beckford A, Ugent S, Goldberg L, Jalisi S, Demierre MF. Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment. Arch Dermatol. 2011 Aug; 147(8):998-9. PMID: 21844475.
    View in: PubMed
  14. Seldin DC, Andrea N, Berenbaum I, Berk JL, Connors L, Dember LM, Doros G, Fennessey S, Finn K, Girnius S, Lerner A, Libbey C, Meier-Ewert HK, O'Connell R, O'Hara C, Quillen K, Ruberg FL, Sam F, Segal A, Shelton A, Skinner M, Sloan JM, Wiesman JF, Sanchorawala V. High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid. 2011 Jun; 18 Suppl 1:127-9. PMID: 21838459.
    View in: PubMed
  15. Vanden Borre P, Near RI, Makkinje A, Mostoslavsky G, Lerner A. BCAR3/AND-34 can signal independent of complex formation with CAS family members or the presence of p130Cas. Cell Signal. 2011 Jun; 23(6):1030-40. PMID: 21262352.
    View in: PubMed
  16. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10; 28(29):4485-91. PMID: 20697094.
    View in: PubMed
  17. Lerner A, Soto J, Rosen JE. Chemotherapy as treatment for colo-colonic intussusception associated with acquired immune deficiency syndrome-related lymphoma. Surgery. 2011 May; 149(5):726-7. PMID: 19962169.
    View in: PubMed
  18. Makkinje A, Near RI, Infusini G, Vanden Borre P, Bloom A, Cai D, Costello CE, Lerner A. AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern. Cell Signal. 2009 Sep; 21(9):1423-35. PMID: 19454314.
    View in: PubMed
  19. Meyers JA, Su DW, Lerner A. Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol. 2009 May 1; 182(9):5400-11. PMID: 19380787.
    View in: PubMed
  20. Near RI, Smith RS, Toselli PA, Freddo TF, Bloom AB, Vanden Borre P, Seldin DC, Lerner A. Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lens. Mol Vis. 2009; 15:685-99. PMID: 19365570.
    View in: PubMed
  21. Rufanova VA, Alexanian A, Wakatsuki T, Lerner A, Sorokin A. Pyk2 mediates endothelin-1 signaling via p130Cas/BCAR3 cascade and regulates human glomerular mesangial cell adhesion and spreading. J Cell Physiol. 2009 Apr; 219(1):45-56. PMID: 19086031.
    View in: PubMed
  22. Garron ML, Arsenieva D, Zhong J, Bloom AB, Lerner A, O'Neill GM, Arold ST. Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in anti-oestrogen resistance. J Mol Biol. 2009 Feb 13; 386(1):190-203. PMID: 19103205.
    View in: PubMed
  23. Near RI, Zhang Y, Makkinje A, Vanden Borre P, Lerner A. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology. J Cell Physiol. 2007 Sep; 212(3):655-65. PMID: 17427198.
    View in: PubMed
  24. Taverna JA, Lerner A, Goldberg L, Werth S, Demierre MF. Infliximab as a therapy for idiopathic hypereosinophilic syndrome. Arch Dermatol. 2007 Sep; 143(9):1110-2. PMID: 17875870.
    View in: PubMed
  25. Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res. 2007 Aug 15; 13(16):4920-7. PMID: 17699872.
    View in: PubMed
  26. Taverna JA, Lerner A, Bhawan J, Demierre MF. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol. 2007 Jul; 6(7):731-2. PMID: 17763598.
    View in: PubMed
  27. Mineva ND, Rothstein TL, Meyers JA, Lerner A, Sonenshein GE. CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis. J Biol Chem. 2007 Jun 15; 282(24):17475-85. PMID: 17446175.
    View in: PubMed
  28. Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol. 2007 Jan; 82(1):23-30. PMID: 16947318.
    View in: PubMed
  29. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J. 2006 Jan 1; 393(Pt 1):21-41. PMID: 16336197.
    View in: PubMed
  30. Felekkis K, Quilliam LA, Lerner A. Characterization of AND-34 function and signaling. Methods Enzymol. 2006; 407:55-63. PMID: 16757314.
    View in: PubMed
  31. Felekkis KN, Narsimhan RP, Near R, Castro AF, Zheng Y, Quilliam LA, Lerner A. AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res. 2005 Jan; 3(1):32-41. PMID: 15671247.
    View in: PubMed
  32. Lerner A, Andrea N. Vinca alkaloids vs. taxanes as therapy in lymphoid malignancies: do our experimental models obscure our understanding of how these drugs really work? Cancer Invest. 2005; 23(1):100-2. PMID: 15779874.
    View in: PubMed
  33. Tiwari S, Dong H, Kim EJ, Weintraub L, Epstein PM, Lerner A. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol. 2005 Feb 1; 69(3):473-83. PMID: 15652238.
    View in: PubMed
  34. Tiwari S, Felekkis K, Moon EY, Flies A, Sherr DH, Lerner A. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. Blood. 2004 Apr 1; 103(7):2661-7. PMID: 14615375.
    View in: PubMed
  35. Cai D, Iyer A, Felekkis KN, Near RI, Luo Z, Chernoff J, Albanese C, Pestell RG, Lerner A. AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res. 2003 Oct 15; 63(20):6802-8. PMID: 14583477.
    View in: PubMed
  36. Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood. 2003 May 15; 101(10):4122-30. PMID: 12531792.
    View in: PubMed
  37. Cai D, Felekkis KN, Near RI, O'Neill GM, van Seventer JM, Golemis EA, Lerner A. The GDP exchange factor AND-34 is expressed in B cells, associates with HEF1, and activates Cdc42. J Immunol. 2003 Jan 15; 170(2):969-78. PMID: 12517963.
    View in: PubMed
  38. Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res. 2002 Oct 15; 62(20):5711-9. PMID: 12384529.
    View in: PubMed
  39. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal. 2002 Mar; 14(3):277-84. PMID: 11812656.
    View in: PubMed
  40. Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin Cancer Res. 2002 Feb; 8(2):589-95. PMID: 11839681.
    View in: PubMed
  41. Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant. 2001 Dec; 28(12):1105-9. PMID: 11803350.
    View in: PubMed
  42. Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma. 2000 Mar; 37(1-2):39-51. PMID: 10721768.
    View in: PubMed
  43. Cai D, Clayton LK, Smolyar A, Lerner A. AND-34, a novel p130Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines. J Immunol. 1999 Aug 15; 163(4):2104-12. PMID: 10438950.
    View in: PubMed
  44. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 1998 Oct 1; 92(7):2484-94. PMID: 9746789.
    View in: PubMed
  45. Lerner A, Yamada T, Miller RA. Pgp-1hi T lymphocytes accumulate with age in mice and respond poorly to concanavalin A. Eur J Immunol. 1989 Jun; 19(6):977-82. PMID: 2666144.
    View in: PubMed
  46. Lerner A, Jacobson B, Miller RA. Cyclic AMP concentrations modulate both calcium flux and hydrolysis of phosphatidylinositol phosphates in mouse T lymphocytes. J Immunol. 1988 Feb 1; 140(3):936-40. PMID: 2828473.
    View in: PubMed
Adam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department